Letrozole Accord

Letrozole, the active ingredient in Letrozole Accord, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the endocrine treatment of hormone‑receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy and for metastatic disease.

GNH USA supplies Letrozole Accord as a licensed, GDP‑compliant international pharmaceutical product serving oncology centres, hospitals and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains and responsive technical support throughout the procurement process.

Letrozole is used in the management of breast cancer, targeting estrogen‑dependent disease pathways. - Hormone receptor‑positive early‑stage breast cancer: improves disease‑free survival as adjuvant therapy. - Hormone receptor‑positive metastatic breast cancer: delays disease progression as first‑line endocrine treatment. - Postmenopausal estrogen‑dependent breast cancer: lowers circulating estrogen to inhibit tumor growth.

Letrozole may cause a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Hot flashes: transient feeling of warmth and sweating. - Arthralgia: joint pain or stiffness. - Fatigue: persistent tiredness. - Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe liver injury: marked elevation of liver enzymes or hepatitis.

When prescribing Letrozole, clinicians should consider several precautionary measures to minimise risk and ensure safe use. - Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation. - Cardiovascular assessment: evaluate risk factors for thrombosis and heart disease before initiation. - Liver function testing: perform baseline and periodic liver enzyme tests. - Drug interactions review: check for concomitant medications that may affect aromatase inhibition. - Pregnancy contraindication: avoid use in pregnant or breastfeeding women; letrozole is category X. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture and light.

Letrozole can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce letrozole plasma levels. - Tamoxifen: concurrent use may antagonize endocrine effects.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): increased risk of bleeding; monitor INR. - SSRIs/SNRIs (fluoxetine, venlafaxine): may affect estrogen metabolism; observe for side effects. - Hormonal contraceptives: reduced efficacy; advise alternative contraception.